Aytu BioPharma Announces 2024 Annual Meeting of Stockholders on June 26

TL;DR

<b>Aytu BioPharma will hold its annual stockholder meeting on June 26, 2024, to elect directors, ratify auditors, and vote on executive compensation.</b>

AI Summary

AYTU BIOPHARMA, INC (AYTU) filed a Proxy Statement (DEF 14A) with the SEC on May 10, 2024. Aytu BioPharma, Inc. will hold its 2024 annual meeting of stockholders on June 26, 2024, at 10:00 a.m. Mountain time. The meeting will take place in person at the offices of Dorsey & Whitney LLP in Denver, Colorado. Key agenda items include the election of five directors, ratification of Grant Thornton LLP as the independent auditor for fiscal year 2024, and an advisory vote on executive compensation. The record date for determining stockholders eligible to vote is April 29, 2024. Stockholders are urged to vote by proxy.

Why It Matters

For investors and stakeholders tracking AYTU BIOPHARMA, INC, this filing contains several important signals. This meeting is a crucial governance event where shareholders will directly influence the company's leadership and financial oversight. The outcomes of the director elections and advisory votes will signal shareholder confidence and potentially impact the company's strategic direction.

Risk Assessment

Risk Level: low — AYTU BIOPHARMA, INC shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.

Analyst Insight

Stockholders should review the proxy materials carefully to make informed decisions regarding director elections and executive compensation.

Key Numbers

• 5 — Directors to be elected (Agenda item for the Annual Meeting)
• June 26, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders)
• April 29, 2024 — Record Date (Date for determining eligible stockholders)
• 2024 — Fiscal Year End (Fiscal year for which Grant Thornton LLP is being ratified as auditor)

Key Players & Entities

• AYTU BIOPHARMA, INC. (company) — Registrant
• June 26, 2024 (date) — Date of Annual Meeting
• Grant Thornton LLP (company) — Independent registered public accounting firm
• April 29, 2024 (date) — Record date for stockholders
• Dorsey & Whitney LLP (company) — Location of meeting

FAQ

Industry Context

Aytu BioPharma, Inc. operates in the pharmaceutical preparations industry, focusing on developing and commercializing products.

Regulatory Implications

The filing is a Schedule 14A (DEF 14A), which is a definitive proxy statement required by the SEC for public companies soliciting shareholder votes.

What Investors Should Do

1. Review the list of director nominees and their qualifications.
2. Understand the proposal to ratify Grant Thornton LLP as the independent auditor.
3. Evaluate the advisory resolution on executive compensation.

Key Dates

• 2024-06-26: Annual Meeting of Stockholders — Election of directors, ratification of auditors, advisory vote on executive compensation.
• 2024-04-29: Record Date — Determines stockholders eligible to vote at the Annual Meeting.

Year-Over-Year Comparison

This filing is a DEF 14A, a routine proxy statement for the annual meeting, and does not represent a change from previous filings in terms of new financial or operational disclosures.

Key Financial Figures

• $250 million — acquisition in 2010 and growth to over $250 million in net sales in 2012. By the time Mr. D

Filing Documents

• aytu20240409_def14a.htm (DEF 14A) — 560KB
• aytuproxy01.jpg (GRAPHIC) — 253KB
• aytuproxy02.jpg (GRAPHIC) — 175KB
• netloss2.jpg (GRAPHIC) — 202KB
• tsr.jpg (GRAPHIC) — 203KB
• 0001437749-24-016003.txt (&nbsp;) — 1709KB

From the Filing

DEF 14A 1 aytu20240409_def14a.htm FORM DEF 14A aytu20240409_def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a12 AYTU BIOPHARMA, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 011 AYTU BIOPHARMA, INC. 7900 E. Union Avenue, Suite 920 Denver, Colorado 80237 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 26, 2024 To the Stockholders of Aytu BioPharma, Inc.: You are cordially invited to attend the 2024 annual meeting of stockholders of Aytu BioPharma, Inc. (the "Annual Meeting") to be held in person on June 26, 2024, at 10:00 a.m. Mountain time at the offices of Dorsey & Whitney LLP, 1400 Wewatta Street, Suite 400, Denver, Colorado 80202 for the following purposes: 1. To elect five directors named in the proxy statement to serve until the next annual meeting of stockholders or until their successors are duly elected and qualified; 2. To ratify the appointment of Grant Thornton LLP ("Grant Thornton") as our independent registered public accounting firm for the fiscal year ending June 30, 2024; 3. To hold an advisory vote on executive compensation; and 4. To act upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof. These matters are more fully described in the proxy statement accompanying this notice. Our board of directors (the "Board" or the "Board of Directors") has fixed the close of business on April 29, 2024, as the record date for the determination of stockholders entitled to notice of and to vote at the Annual Meeting, or any adjournment thereof. A list of stockholders eligible to vote at the Annual Meeting will be available for review during our regular business hours at our principal offices in Denver, Colorado for 10 days prior to the Annual Meeting. To assure your representation at the Annual Meeting, you are urged to vote by proxy by following the instructions contained in the proxy statement. You may revoke your proxy or change your vote for shares of our common stock you hold directly in your name through our transfer agent, Issuer Direct Corporation, by (i) signing another proxy card with a later date and delivering it to our Corporate Secretary at 7900 E. Union Avenue, Suite 920, Denver, Colorado 80237 before the date of the Annual Meeting, (ii) submitting revised votes over the Internet or by telephone by 11:59 p.m. Eastern time on June 25, 2024, or (iii) attending the Annual Meeting and voting your shares of our common stock in person at our Annual Meeting. If your shares of common stock are held in the name of a bank, broker, or other nominee holder of record, please follow the instructions on the voting instruction form furnished to you by such record holder. Denver, Colorado Dated: May 10, 2024 By Order of the Board of Directors /s/ Joshua R. Disbrow Joshua R. Disbrow Chairman and Chief Executive Officer 1 AYTU BIOPHARMA, INC. 7900 E. Union Avenue, Suite 920 Denver, Colorado 80237 PROXY STATEMENT DATED MAY 10, 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON WEDNESDAY, JUNE 26, 2024 This proxy statement has been prepared by the management of Aytu BioPharma, Inc. "We," "our," "Aytu," and the "Company" each refers to Aytu BioPharma, Inc. and its wholly owned subsidiaries. The enclosed proxy is solicited by the Board of Directors of the Company for use at the 2024 annual meeting of stockholders of the Company (the "Annual Meeting") and at any postponement or adjournment thereof. In accordance with the rules of the United States Securities and Exchange Commission ("SEC"), instead of mailing a printed copy of our proxy materials to each stockholder of record, we are furnishing a Notice of Internet Availability of Proxy Materials (the "Notice of Internet Availability") and providing Internet access to our proxy materials, including the notice, this proxy statement, our annual report to stockholders, including financial statements, and a proxy card for the Annual Meeting, which will save printing costs and benefit the environment. These materials will first be available on the Internet on or about May 10, 2024. If you are a stockholder of record or a beneficial owner as of the record date of April 29, 2024, we will mail a No

View Full Filing

View this DEF 14A filing on SEC EDGAR